ZYP Medical sells to seven named states and prices most of its catalogue in four-week and six-week blocks rather than by the month, printing the unit beside almost every figure. It states in its own words that its compounded semaglutide, tirzepatide and NAD+ are not FDA-approved.
What ZYP Medical charges
Semaglutide: $150/mo — from; "Medication is included in the monthly price; final pricing depends on your prescribed dose"
Tirzepatide: $233/mo — from; a needle-free tirzepatide ODT is priced separately at $250 a month
NAD+: $179 — one-time, for a six-week titration; maintenance is then $249 every six weeks
BPC-157: $259 — all-inclusive for four weeks, one vial; the stack pairs BPC-157 with TB-500 and is not a price for either alone
ZYP Medical also sells 5 compounds this site boards without publishing a price for them: Glutathione, TB-500 (board ranks no provider), Tesamorelin, Ipamorelin (board ranks no provider) and CJC-1295 (board ranks no provider).
ZYP Medical is not a paid partner; this link may earn a commission if that changes. Full disclosure.
By Nora Castellan, Standards EditorUpdated September 2026
Almost nothing here is priced by the month, and the seller says so
Its peptide stacks are sold as four weeks, all-inclusive. Its injectable NAD+ is a one-time charge for a six-week titration and then a recurring charge every six weeks.
Its tablets and capsules are one-time purchases for thirty, sixty or ninety-day supplies; only the nasal spray and the category floors say per month.
Every figure recorded from this seller carries the seller's own unit with it, because a four-week block read as a month understates what a year costs.
Seven states, listed by name
Its telehealth weight-loss and urgent-care line names Nebraska, Iowa, South Dakota, Minnesota, Kansas, Colorado and Arizona.
That is a list rather than a count, which is what makes it checkable.
A narrower list applies to testosterone only, where the page says the practice holds federal licensure to prescribe in three of those seven. That is a different product line and does not change the seven.
Its own words on legal category
It writes that "Compounded semaglutide and tirzepatide are NOT FDA-approved and are prescribed off-label, when clinically appropriate, by a licensed provider through licensed compounding pharmacies."
Its NAD+ page adds "Compounded NAD+ is not FDA-approved."
It also says of itself that it "is a medical practice, not a pharmacy, and does not dispense or ship medication", which is a description of its role rather than a pharmacy name.
A stack price is not a peptide price
Its tissue-repair stack is sold as a single vial covering four weeks, all-inclusive, and it pairs BPC-157 with TB-500.
That figure buys two compounds at once, so it is not a price for either one alone and is not treated as one here.
Most of the peptide catalogue is built the same way, which limits how far this seller can be compared against one that prices a single compound.
Who it's for
Readers inside one of the seven states it names.
Buyers who want the billing period printed next to the number.
Shoppers who want the non-approval statement made plainly rather than buried.
Anyone comparing multi-compound stacks rather than single peptides.
Who should look elsewhere
Readers in the rest of the country, which is most of it.
Buyers who want a single peptide priced on its own.
Anyone who needs the dispensing pharmacy named.
Shoppers wanting testosterone outside the three states that line reaches.
Strengths
Names the seven states it serves rather than printing a count
States plainly that its compounded semaglutide, tirzepatide and NAD+ are not FDA-approved
Prints the unit beside almost every figure — four weeks, six weeks, one-time, per month
Says its consult fee buys clinical time and does not guarantee a prescription
Trade-offs
Prices most of its peptide catalogue as multi-compound stacks, so no single peptide has its own figure
Names no dispensing pharmacy and publishes no certificate of analysis
Serves seven states, so most of the country cannot buy from it
Its testosterone line reaches only three of those seven states, which the page states separately
How we verified this
Read the unit printed beside each figure and recorded the seller's own words for it — four weeks, six weeks, one-time or per month — rather than normalising anything to a month.
Recorded the seven-state list as printed and kept the narrower testosterone list separate, because it governs a different product line.
Quoted its non-approval sentences from the pages that carry them rather than paraphrasing them.
Requested a deliberately meaningless address on this host in the same session and confirmed it returns a not-found response.
Screened the brand against the live federal warning-letter table through a matcher that normalises both the query and the filed company name before comparing, pulling all 3,677 records in pages and filtering locally because the table's own search parameter is ignored, with a positive and a nonsense control in the same run.
A provider to compare ZYP Medical against
Trellis Vitality
Trellis Vitality frames its program around body-composition tracking rather than scale weight, pairing NAD+, glutathione and tesamorelin with at-home biomarker panels and a 90-day re-test, and names its dispensing pharmacy, VialsRX in Houston, by address.
Nebraska, Iowa, South Dakota, Minnesota, Kansas, Colorado and Arizona for its telehealth weight-loss and urgent-care line. Testosterone is limited to three of those seven.
Are its prices monthly?
Mostly not. Peptide stacks are four-week blocks, NAD+ runs on six-week cycles, and tablets and capsules are one-time purchases for fixed supplies.
Does it say its medicines are FDA-approved?
It says the opposite. Its own pages state that its compounded semaglutide, tirzepatide and NAD+ are not FDA-approved and are prescribed off-label.
Can I get BPC-157 on its own?
Not at a published price. Its BPC-157 figure covers a stack that also contains TB-500, so it is not a price for either compound alone.
ZYP Medical is not a paid partner; this link may earn a commission if that changes. Full disclosure.